During the COVID-19 pandemic, medicines shortages were observed worldwide. In this context, the US Pharmacopeia and pharmaceutical chain representatives will share their actions to make the supply chain more resilient. ANVISA will bring its perspectives on lessons learned by regulators during this period, such as the adoption of regulatory reliance, and how it is preparing to face the next public health emergency.
The event aims to discuss trends and perspectives to strengthen supply chain resilience of quality medicines.
Learn more about our Speakers
|
Topics
|
Speaker
|
| USP’s future trends and perspectives to support supply chain resilience |
Ronald T. Piervincenzi, CEO - US Pharmacopeia |
| Lessons learned by regulatory authorities and preparation for the next public health emergency to avoid drug shortages |
Antonio Barra Torres, Director Chairman - ANVISA
|
| Reliance to improve regulatory processes and access to safe, effective and quality-assured medicines |
Fabrício Carneiro de Oliveira, GGBIO/ANVISA |
| Efforts of Brazilian industry to avoid drug shortage during COVID-19 pandemic |
Rosana Mastellaro, SINDUSFARMA
Norberto Prestes, ABIQUIFI
|
| Importance of collaborative efforts to maintain integrity and avoid drug shortages - Case: RDC No. 430/2020 (Good Distribution, Transport and Storage Practices) |
Oscar Yazbek Filho, ABAFARMA;
Renato A. Porto, ABRAFARMA;
Rosana Mastellaro, SINDUSFARMA
Gylson Ribeiro, NTC&Logística
|
| USP Latin America Overview |
Nilton Tojar, Regional Director – US Pharmacopeia Latin America |
| USP efforts on Good Distribution, Transport and Storage Practices |
Luciana Takara, US Pharmacopeia
Glaucia Braga, USP Expert Committee |
|
